

MINUTES
September 17, 2001 Meeting
DRUG UTILIZATION REVIEW (DUR) BOARD

Members present: Pat Churchill, Herb Wilson, Brendan Joyce, Marty Meese, Bob Treitline, Karen Shimek, Greg Pfister

Guests Present: Calvin Rolfson – PhRMA, Kelly Marshall – Pharmacia, David Peske – ND Medical Association, Laura Randa King – Purdue Pharma

Members absent: Mark Biel

The meeting was opened at 8:00 AM in Conference Room D. Past minutes were circulated and accepted as received.

Old Business

1. New Member Update – Progress in finding additional physician members has been slow. Further requests for potential members were made.
2. Migraine Products – Two cases were reviewed due to their nature of excessive utilization. It was agreed that letters could be sent from the DUR Board to the providers asking for additional information on the utilization of the products (Stadol NS and Zomig) for these two patients. This led to a discussion regarding what tools are allowed for Medicaid to assist with proper utilization. Increased prospective DUR activity was determined to be the most feasible.
3. Orlistat update – Letters that were sent out during the previous week were reviewed as were the two responses received thus far. Results from all responses will be disseminated to the DUR Board prior to the next meeting.

New Business

1. Patient Reviews – All attending members gave a brief overview of the findings of their patient reviews. One patient and provider will be reviewed for Lock-in / fraud issues. Letters will be generated to address a variety of other issues brought to the DUR Board's attention.
2. Compounds – Compound prescriptions were discussed in detail. It was agreed that any ND Medicaid specific NDC that had not been used within the last year could be eliminated from coverage. Compounds of commercially available and rebatable products were discussed and it was recommended that exact duplicates should not be paid and special formulations (eg. preservative free) should be paid equal to a post rebate price of the commercial product as determined by the

- Department of Human Services. It was recommended that the Department of Human Services process compound claims in the future (NCPDP 5.1) as follows: if there is at least one NDC that is payable, process and price the prescription based on all NDC's regardless of coverage. If no NDC is payable, deny the prescription.
3. Physician contact for specific cases – A variety of “off-label” use and dosing was reviewed by the board. It was recommended that the Department of Human Services send the physicians letters as well as move toward a better utilization of Prospective DUR edits to prevent such claims from being paid.
 4. DUR Letters – Some example letters were reviewed as well as responses from the physicians. It was recommended that the letters continue to focus on the same issues and be mailed out quarterly at a maximum.

Suggestions were taken for the next agenda and the meeting was adjourned.

The next meeting will be January 14 at 8:00 AM in conference room D, Judicial Wing, State Capital.